Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options.

Amaador K, Peeters H, Minnema MC, Nguyen TQ, Dendooven A, Vos JMI, Croockewit AJ, van de Donk NWCJ, Jacobs JFM, Wetzels JFM, Sprangers B, Abrahams AC.

Neth J Med. 2019 Sep;77(7):243-254.

2.

Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor.

Bilgin YM, Visser O, Beckers EA, te Boome LC, Huisman C, Ypma PF, Croockewit AJ, Netelenbos T, Kramer EP, de Greef GE.

Transfusion. 2015 May;55(5):1021-7. doi: 10.1111/trf.12979. Epub 2014 Dec 30.

PMID:
25641128
3.

Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.

Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, Schuurhuis DH, Mus R, Thielemans K, de Vries IJ, Figdor CG, Punt CJ, Adema GJ.

Clin Cancer Res. 2012 Oct 1;18(19):5460-70. doi: 10.1158/1078-0432.CCR-11-3368. Epub 2012 Aug 15.

4.

Bullous lesions of the vulvar region revealing both AL amyloidosis and vulvar carcinoma.

Van De Nieuwenhof HP, Croockewit AJ, Van Der Avoort IA, Bekkers RL, De Hullu JA.

Amyloid. 2008 Sep;15(3):210-2. doi: 10.1080/13506120802193431.

PMID:
18925460
5.

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.

Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Haematologica. 2007 Jul;92(7):928-35.

6.

Splenectomy for the treatment of thrombotic thrombocytopenic purpura.

Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT, Löwenberg B, Brand A.

Br J Haematol. 2005 Sep;130(5):768-76. Review.

PMID:
16115135
7.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

PMID:
12456509
8.

[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].

Croockewit AJ, de Boer JE, van Loenhout JW, Koopmans PP.

Ned Tijdschr Geneeskd. 2002 Jun 15;146(24):1117-20. Review. Dutch. Erratum in: Ned Tijdschr Geneeskd 2002 Aug 24;146(34):1612.

PMID:
12092301
9.

Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.

Vellenga E, van Agthoven M, Croockewit AJ, Verdonck LF, Wijermans PJ, van Oers MH, Volkers CP, van Imhoff GW, Kingma T, Uyl-de Groot CA, Fibbe WE.

Br J Haematol. 2001 Aug;114(2):319-26.

PMID:
11529850
10.

[Interferon for adjuvant therapy of melanoma: approved, not indicated].

Croockewit AJ, Koopmans PP, Lekkerkerker JF.

Ned Tijdschr Geneeskd. 2001 Mar 10;145(10):498-9. Dutch. No abstract available.

PMID:
11268915
11.

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.

Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM.

Br J Haematol. 1999 Apr;105(1):127-30.

PMID:
10233375
12.

The low cycling status of mobilized peripheral blood CD34+ cells is not restricted to the more primitive subfraction.

Croockewit AJ, Raymakers RA, Smeets ME, vd Bosch G, Pennings AH, de Witte TJ.

Leukemia. 1998 Apr;12(4):571-7.

13.

A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC.

Croockewit AJ, Bronchud MH, Aapro MS, Bargetzi MJ, Crown J, Gratwohl A, Lange W, Ludwig H, Martinelli G, Mertelsmann R, Nuessler V, Willemze R, De Witte TJ, Zittoun R, Zwierzina H.

Eur J Cancer. 1997 Oct;33(11):1732-46. Review. No abstract available.

PMID:
9470826
14.

The role of the different CD34 epitopes in detection and positive selection of CD34+ bone marrow and peripheral blood stem cells.

Croockewit AJ, Raymakers RA, Preijers FW, Vierwinden G, de Witte TJ.

Scand J Immunol. 1998 Jan;47(1):82-90.

15.

Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy?

Croockewit AJ, Koopmans PP, de Pauw BE.

Clin Pharmacol Ther. 1996 Jan;59(1):1-6. Review. No abstract available.

PMID:
8549028
16.

Rebound of anti-topoisomerase I antibody titres after plasma exchange.

Van den Hoogen FH, Boerbooms AM, Van de Putte LB, Verheijen R, Van Venrooij W, Croockewit AJ.

Ann Rheum Dis. 1993 Mar;52(3):246-7. No abstract available.

Supplemental Content

Loading ...
Support Center